Metalink (MTLK) 20-F 29 Apr 21 2020 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document And Entity Information
Entity Registrant Name	METALINK LTD
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	1,255,640
Amendment Flag	false
Entity Central Index Key	0001098462
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	true
Document Annual Report	true
Document Shell Company Report	false
Document Transition Report	false
Entity File Number	000-30394
Entity Incorporation, State or Country Code	L3
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 301	$ 12
Bank deposits	1,624	1,919
Total assets	1,925	1,931
Current liabilities
Other payables and accrued expenses	159	142
Total current liabilities	159	142
Shareholders' equity
Ordinary shares of NIS 1.0 par value (5,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 2,780,707 shares issued and 1,255,640 shares outstanding as of December 31, 2020 and December 31, 2019)	790	790
Additional paid-in capital	158,111	158,111
Accumulated deficit	(145,097)	(145,074)
Total shareholders' equity before reduction of treasury stock	13,804	13,827
Treasury stock, at cost: 1,525,067 shares as of December 31, 2020 and December 31, 2019	(12,038)	(12,038)
Total shareholders' equity	1,766	1,789
Total liabilities and shareholders' equity	$ 1,925	$ 1,931

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - ₪ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Ordinary shares, par value (in New Shekels per share)	₪ 1	₪ 1
Ordinary shares, shares authorized	5,000,000	5,000,000
Ordinary shares, shares issued	2,780,707	2,780,707
Ordinary shares, shares outstanding	1,255,640	1,255,640
Treasury shares	1,525,067	1,525,067

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
General and administrative (includes director fees in the amount of $8, $7 and $2 in 2020, 2019 and 2018, respectively)	$ 48	$ 45	$ 58
Operating loss	(48)	(45)	(58)
Financial income, net	25	49	23
Net profit (loss)	$ (23)	$ 4	$ (35)
Per share data-
Basic and diluted earnings (loss) (in Dollars per share)	$ (0.018)	$ 0.003	$ (0.028)
Shares used in computing earnings (loss) per ordinary share:
Basic and diluted (in Shares)	1,255,640	1,255,640	1,255,640

STATEMENTS OF OPERATIONS (Paren

STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Director fees	$ 8	$ 7	$ 2

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Share Capital	Treasury Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at beginning, value at Dec. 31, 2017	$ 790	$ (12,038)	$ 158,111	$ (145,043)	$ 1,820
Balance at beginning, shares at Dec. 31, 2017	2,780,707	1,525,067
Net loss for the year				(35)	(35)
Balance at ending, value at Dec. 31, 2018	$ 790	$ (12,038)	158,111	(145,078)	1,785
Balance at ending, shares at Dec. 31, 2018	2,780,707	1,525,067
Net loss for the year				4	4
Balance at ending, value at Dec. 31, 2019	$ 790	$ (12,038)	158,111	(145,074)	1,789
Balance at ending, shares at Dec. 31, 2019	2,780,707	1,525,067
Net loss for the year				(23)	(23)
Balance at ending, value at Dec. 31, 2020	$ 790	$ (12,038)	$ 158,111	$ (145,097)	$ 1,766
Balance at ending, shares at Dec. 31, 2020	2,780,707	1,525,067

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net profit (loss)	$ (23)	$ 4	$ (35)
Adjustments required to reconcile net profit (loss) to net cash provided by (used in) operating activities (Appendix A)
Deposit revaluation*	(5)	(15)	(4)
Increase (decrease) in operating liabilities:
Other payables and accrued expenses	17	1	(5)
Net cash (used in) continuing operating activities	(11)	(10)	(44)
Cash flows from investing activities:
Deposits	300	(2)	(1,898)
Net cash provided by (used in) investing activities	300	(2)	(1,898)
Increase (decrease) in cash and cash equivalents	289	(12)	(1,942)
Cash and cash equivalents at beginning of year	12	24	1,966
Cash and cash equivalents at end of year	$ 301	$ 12	$ 24

NOTE 1 - GENERAL

NOTE 1 - GENERAL	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
NOTE 1 - GENERAL	NOTE 1 GENERAL Metalink Ltd. (hereinafter: the "Company") is an Israeli company incorporated in September 1992, which until the sale of its WLAN operations in February 2010 was engaged in the WLAN business (see Note 4) and since then, conducted only limited business activities related to its DSL business, which, since March 2016, it no longer conducts. The Company's current plan of operation is to consider strategic alternatives, including a possible business combination, other strategic transaction with a domestic or foreign, private or public operating entity or a "going private" transaction, including with any of its affiliates, and, to a limited extent, voluntary liquidation.

NOTE 2 - SIGNIFICANT ACCOUNTING

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 SIGNIFICANT ACCOUNTING POLICIES The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A. Use of Estimates in Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. B. Financial Statements in U.S. Dollars The reporting currency of the Company is the U.S. dollar ("dollar" or "$"). The currency of the primary economic environment in which the operations of the Company are conducted is the dollar, and the dollar has been determined to be the Company's functional currency. Transactions and balances originally denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured into dollars in accordance with the principles set forth in Accounting Standards Codification ("ASC") No. 830 (“Foreign Currency Matters”). All exchange gains and losses from re-measurement of monetary balance sheet items resulting from transactions in non-dollar currencies are reflected in the statements of operations as they arise. C. Cash Equivalents Cash equivalents consist of short-term, highly liquid investments like bank deposits, which are readily convertible into cash with original maturities when purchased of three months or less. D. Net Profit (Loss) Per Ordinary Share Basic net profit (loss) per ordinary share was computed in accordance with ASC No. 260-10 by dividing the net profit (loss) allocated to ordinary shareholders by the weighted-average number of ordinary shares outstanding during the period. For purposes of calculating diluted earnings per ordinary share, the denominator includes both the weighted-average number of ordinary shares outstanding during the period and the number of ordinary share equivalents if the inclusion of such ordinary share equivalents is dilutive. Dilutive ordinary share equivalents potentially include stock options using the treasury stock method. In 2020 and 2018, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per ordinary share was the same. In 2019, the stock options were "out of the money" and therefore, basic and diluted loss per ordinary share was the same. E. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and bank deposits. As of December 31, 2020, the Company had cash and cash equivalents that totaled to $301 and short-term deposits totaling to $1,624 all of which are deposited in a major Israeli financial institution. As of December 31, 2019, the Company had cash and cash equivalents that totaled to $12 and short-term deposits totaling to $1,919 all of which were deposited in a major Israeli financial institution. The Company has not incurred any losses on these accounts. Management believes that the financial institutions holding the Company's cash and cash equivalents and its deposits is financially sound. F. Fair Value of Financial Instruments The carrying value of cash and cash equivalents, and other payables and accrued expenses approximated their fair values as of December 31, 2020 and 2019 due to their short-term nature. G. Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company’s financial statements.

NOTE 3 - BANK DEPOSITS

NOTE 3 - BANK DEPOSITS	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
NOTE 3 - BANK DEPOSITS	NOTE 3 BANK DEPOSITS The Company’s bank deposits are denominated in U.S. dollars and bare different interest rates ranging from 0.37% to 0.53% depending on their maturity, which ranges from 6 to 12 months.

NOTE 4 - CONTINGENT LIABILITIES

NOTE 4 - CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
NOTE 4 - CONTINGENT LIABILITIES	NOTE 4 CONTINGENT LIABILITIES In August 30, 2011, the Company received a letter from Tmura Fund, operating within the Israel Innovation Authority (formerly known as the Office of the Chief Scientist) of the Israeli Ministry of Economy) (the "IAA") according to which - the Company is required to pay the IAA a sum of NIS 943 thousand ($293 thousand) for royalties on the basis of income derived from the sale of the WLAN business to Lantiq. On September 15, 2011 the Company replied that it disagrees with the IAA position. As of the filing of this report, the disagreement has not been resolved. The Company is of the opinion that the demand has no merits and intends to vigorously defend its case. Despite this opinion, the Company recorded a provision in the amount of USD $128 thousand, included in other payables and accrued expenses, intended for potential legal claims against the Company for the above mentioned demand dated August 30, 2011. See Note 7.

NOTE 5 - SHARE CAPITAL

NOTE 5 - SHARE CAPITAL	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
NOTE 5 - SHARE CAPITAL	NOTE 5 SHARE CAPITAL Stock Options (i) In January 2012, the Company granted its former CEO, Tzvika Shukhman, options to purchase up to 100,000 ordinary shares of Metalink, in accordance with the following terms: (i) exercise price equal to $1.50 per share; (ii) the options vested fully on December 31, 2013; (iii) the options expiration date is set 10 years from date of grant, i.e. December 31, 2021; Those options are treated as equity instruments issued to other than employees. (ii) During 2012, the Board of Directors decided to grant its former director, Hudi Zak, options to purchase up to 12,500 ordinary shares of Metalink, in accordance with the following terms: (i) exercise price equal to $1.50 per share; (ii) the options are all fully vested upon the grant; (iii) the options expiration date is set 10 years from date of grant. A summary of the status of the Company's stock option activities to employees and directors of the Company as of and the year ended December 31, 2020, 2019 and 2018 are as follows: December 31, 2020 December 31, 2019 December 31, 2018 Weighted Weighted Weighted average average average exercise exercise exercise Shares price Shares price Shares price Options outstanding at beginning of year 112,500 1.50 112,500 1.50 112,500 1.50 Outstanding and exercisable at end of year 112,500 1.50 112,500 1.50 112,500 1.50 The aggregate intrinsic value is $0 for all years presented in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.43 as of December 31, 2020, $0.40 as of December 31, 2019, and $0.39 as of December 31, 2018, which would have been received by the option holders had all option holders exercised their options as of that date.

NOTE 6 - TAXES ON INCOME

NOTE 6 - TAXES ON INCOME	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
NOTE 6 - TAXES ON INCOME	NOTE 6 TAXES ON INCOME A. Taxation under Various Laws (i) The Company is assessed under the provisions of the Israeli Income Tax Ordinance. (ii) Income derived from sources other than the "Approved Enterprise" is taxable at the ordinary corporate tax rate of 23% (regular "Company Tax"). B. Reconciliation of Income Taxes The following is a reconciliation of the taxes on income assuming that all income is taxed at the ordinary statutory corporate tax rate in Israel and the effective income tax rate: Year ended December 31, 2 0 2 0 2 0 1 9 2 0 1 8 Net profit (loss) as reported in the statements of operations (23) 4 (35) Statutory tax rate 23.0% 23.0 % 23.0 % Income Tax under statutory tax rate (5.3) 1 (8) Less full valuation allowance 5.3 (1) 8 Provision for income tax - - - C. Deferred Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of December 31, 2020, 2019 and 2018. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during 2020, 2019 and 2018. Tax losses carried forward of the Company as of 31 December 2018 are $193 million (NIS 726 million), as of December 2019 $210 million (NIS 726 million) and expected to be $226 million (NIS 726 million) as of December 2020. This loss is unlimited in duration and denominated in nominal NIS (the dollar balance translated according to the exchange rate at year end, and therefore fluctuates significantly through the periods). D. Tax Assessments The Company has not received final tax assessments for income tax purposes since incorporation. However, according to Israeli tax laws assessments considered final until and including the year ended in 2015.

NOTE 7 - SUPPLEMENTARY BALANCE

NOTE 7 - SUPPLEMENTARY BALANCE SHEET INFORMATION	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
NOTE 7 - SUPPLEMENTARY BALANCE SHEET INFORMATION	NOTE 7 SUPPLEMENTARY BALANCE SHEET INFORMATION Other Payables and Accrued Expenses December 31, 2 0 2 0 2 0 2 0 Provision for legal claims 128 128 Accrued expenses (in 2020 includes $8 to directors) 26 14 154 142

NOTE 8 - SUPPLEMENTARY STATEMEN

NOTE 8 - SUPPLEMENTARY STATEMENT OF OPERATIONS INFORMATION	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
NOTE 8 - SUPPLEMENTARY STATEMENT OF OPERATIONS INFORMATION	NOTE 8 SUPPLEMENTARY STATEMENT OF OPERATIONS INFORMATION Financial Income December 31, 2 0 2 0 2 0 1 9 Interest income 49 25 Income (expense) from revaluation of deposits (24) 24 25 49

NOTE 9 - SIGNIFICANT EVENTS DUR

NOTE 9 - SIGNIFICANT EVENTS DURING THE REPORTED PERIOD (COVID-19)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
NOTE 9 - SIGNIFICANT EVENTS DURING THE REPORTED PERIOD (COVID-19)	NOTE 9 SIGNIFICANT EVENTS DURING THE REPORTED PERIOD (COVID-19) Since January 2020 and until the filing of this report, the world is experiencing a pandemic that is having a macro-economic impact relating to the spread of the Covid-19 (Corona) virus (hereinafter “the Virus”). Corona has been declared a pandemic by the World Health Organization. Many countries, including Israel, have taken significant steps in an effort to minimize the spread of the Virus, such as restrictions on citizens, transportation of passengers and goods, reducing the number of employees who are allowed to get to work, etc. This event has significant effects on the economies and world markets, and many countries were economically harmed by the spread of the Virus. The Company's management is of the opinion that, as of the issuance of this report, there is no effect on the scope of the Company’s operations. In case the Company will have an investment and/or new activity in the near future, at this stage the Company does not know in which sector or industry it will be, hence it does not know how to assess the possible impact of the Virus on the investment/new activity.

NOTE 2 - SIGNIFICANT ACCOUNTI_2

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates in Preparation of Financial Statements	A. Use of Estimates in Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.
Financial Statements in U.S. Dollars	B. Financial Statements in U.S. Dollars The reporting currency of the Company is the U.S. dollar ("dollar" or "$"). The currency of the primary economic environment in which the operations of the Company are conducted is the dollar, and the dollar has been determined to be the Company's functional currency. Transactions and balances originally denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured into dollars in accordance with the principles set forth in Accounting Standards Codification ("ASC") No. 830 (“Foreign Currency Matters”). All exchange gains and losses from re-measurement of monetary balance sheet items resulting from transactions in non-dollar currencies are reflected in the statements of operations as they arise.
Cash Equivalents	C. Cash Equivalents Cash equivalents consist of short-term, highly liquid investments like bank deposits, which are readily convertible into cash with original maturities when purchased of three months or less.
Net Profit (Loss) Per Ordinary Share	D. Net Profit (Loss) Per Ordinary Share Basic net profit (loss) per ordinary share was computed in accordance with ASC No. 260-10 by dividing the net profit (loss) allocated to ordinary shareholders by the weighted-average number of ordinary shares outstanding during the period. For purposes of calculating diluted earnings per ordinary share, the denominator includes both the weighted-average number of ordinary shares outstanding during the period and the number of ordinary share equivalents if the inclusion of such ordinary share equivalents is dilutive. Dilutive ordinary share equivalents potentially include stock options using the treasury stock method. In 2020 and 2018, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per ordinary share was the same. In 2019, the stock options were "out of the money" and therefore, basic and diluted loss per ordinary share was the same.
Concentrations of Credit Risk	E. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and bank deposits. As of December 31, 2020, the Company had cash and cash equivalents that totaled to $301 and short-term deposits totaling to $1,624 all of which are deposited in a major Israeli financial institution. As of December 31, 2019, the Company had cash and cash equivalents that totaled to $12 and short-term deposits totaling to $1,919 all of which were deposited in a major Israeli financial institution. The Company has not incurred any losses on these accounts. Management believes that the financial institutions holding the Company's cash and cash equivalents and its deposits is financially sound.
Fair Value of Financial Instruments	F. Fair Value of Financial Instruments The carrying value of cash and cash equivalents, and other payables and accrued expenses approximated their fair values as of December 31, 2020 and 2019 due to their short-term nature.
Recently Issued Accounting Pronouncements	G. Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company’s financial statements.

NOTE 5 - SHARE CAPITAL (Tables)

NOTE 5 - SHARE CAPITAL (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of stock option activities	A summary of the status of the Company's stock option activities to employees and directors of the Company as of and the year ended December 31, 2020, 2019 and 2018 are as follows: December 31, 2020 December 31, 2019 December 31, 2018 Weighted Weighted Weighted average average average exercise exercise exercise Shares price Shares price Shares price Options outstanding at beginning of year 112,500 1.50 112,500 1.50 112,500 1.50 Outstanding and exercisable at end of year 112,500 1.50 112,500 1.50 112,500 1.50

NOTE 6 - TAXES ON INCOME (Table

NOTE 6 - TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The following is a reconciliation of the taxes on income assuming that all income is taxed at the ordinary statutory corporate tax rate in Israel and the effective income tax rate: Year ended December 31, 2 0 2 0 2 0 1 9 2 0 1 8 Net profit (loss) as reported in the statements of operations (23) 4 (35) Statutory tax rate 23.0% 23.0 % 23.0 % Income Tax under statutory tax rate (5.3) 1 (8) Less full valuation allowance 5.3 (1) 8 Provision for income tax - - -

NOTE 7 - SUPPLEMENTARY BALANCE

NOTE 7 - SUPPLEMENTARY BALANCE SHEET INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
Schedule of Other Payables and Accrued Expenses	Other Payables and Accrued Expenses December 31, 2 0 2 0 2 0 1 9 Provision for legal claims 128 128 Accrued expenses (in 2020 includes $8 to directors) 31 14 159 142

NOTE 8 - SUPPLEMENTARY STATEM_2

NOTE 8 - SUPPLEMENTARY STATEMENT OF OPERATIONS INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Schedule of Financial Income	Financial Income December 31, 2 0 2 0 2 0 1 9 Interest income 49 25 Income (expense) from revaluation of deposits (24) 24 25 49

NOTE 2 - SIGNIFICANT ACCOUNTI_3

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 301	$ 12	$ 24	$ 1,966
Short-term deposits	$ 1,624	$ 1,919

NOTE 3 - BANK DEPOSITS (Details

NOTE 3 - BANK DEPOSITS (Details)	12 Months Ended
	Dec. 31, 2020
Minimum [Member]
Interest rate	0.37%
Maturity term	6 months
Maximum [Member]
Interest rate	0.53%
Maturity term	12 months

NOTE 4 - CONTINGENT LIABILITI_2

NOTE 4 - CONTINGENT LIABILITIES (Details) $ in Thousands	1 Months Ended
	Aug. 30, 2011USD ($)
Commitments and Contingencies Disclosure [Abstract]
Payments for royalties	$ 293
Provision for contingent liabilities	$ 128

NOTE 5 - SHARE CAPITAL (Details

NOTE 5 - SHARE CAPITAL (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 12, 2012	Dec. 31, 2012	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Capital (Details) [Line Items]
Stock price			$ 0.43	$ 0.40	$ 0.39
Intrinsic value of option			$ 0
Tzvika Shukhman [Member]
Share Capital (Details) [Line Items]
Ordinary shares	100,000
Exercise price	$ 1.50
Expiration period	10 years
Hudi Zak [Member]
Share Capital (Details) [Line Items]
Ordinary shares		12,500
Exercise price		$ 1.50
Expiration period		10 years

NOTE 5 - SHARE CAPITAL _ Schedu

NOTE 5 - SHARE CAPITAL : Schedule of stock option plans to employees and directors (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of stock option plans to employees and directors [Abstract]
Shares,Options outstanding at beginning of year	112,500	112,500	112,500
Weighted average exercise Price, Options outstanding at beginning of year (in Dollars per share)	$ 1.5	$ 1.5	$ 1.5
Shares, Granted during year
Weighted average exercise Price, Granted during year (in Dollars per share)
Shares,Outstanding at end of year	112,500	112,500	112,500
Weighted average exercise Price, Outstanding at end of year (in Dollars per share)	$ 1.5	$ 1.5	$ 1.5
Shares, Options exercisable at end of year	112,500	112,500	112,500
Weighted average exercise Price, Options exercisable at end of year (in Dollars per share)	$ 1.5	$ 1.5	$ 1.5

NOTE 6 - TAXES ON INCOME (Detai

NOTE 6 - TAXES ON INCOME (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Ordinary corporate tax rate	23.00%	23.00%
Deferred tax loss carry forwards	$ 226	$ 210	$ 193
Uncertain tax positions	$ 0	$ 0	$ 0

NOTE 6 - TAXES ON INCOME _ Sche

NOTE 6 - TAXES ON INCOME : Schedule of reconciliation of income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of reconciliation of income taxes [Abstract]
Net profit (loss) as reported in the statements of operations	$ (23,000)	$ 4,000	$ (35,000)
Statutory tax rate	23.00%	23.00%	24.00%
Income Tax under statutory tax rate	$ (5,300)	$ 1,000	$ (8,000)
Less full valuation allowance	5,300	(1,000)	8,000
Actual income tax	$ 0	$ 0	$ 0

NOTE 7 - SUPPLEMENTARY BALANC_2

NOTE 7 - SUPPLEMENTARY BALANCE SHEET INFORMATION : Schedule of other payables and accrued expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of other payables and accrued expenses [Abstract]
Provision for legal claims	$ 128	$ 128
Accrued expenses (in 2020 includes $8 to directors)	31	14
Other payables and accrued expenses	$ 159	$ 142

NOTE 8 - SUPPLEMENTARY STATEM_3

NOTE 8 - SUPPLEMENTARY STATEMENT OF OPERATIONS INFORMATION : Schedule of financial income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of other payables and accrued expenses [Abstract]
Interest income	$ 49	$ 25
Income (expense) from revaluation of deposits	(24)	24
Financial Income	$ 25	$ 49